Cargando…

Practical Guidance for the Use of Long-Acting Injectable Antipsychotics in the Treatment of Schizophrenia

Schizophrenia is a severe mental illness causing a high degree of disability. First- and second-generation antipsychotics (FGAs and SGAs) represent key resources for its acute and long-term management. Since a poor adherence to oral treatments may negatively impact the course of the disorder, long-a...

Descripción completa

Detalles Bibliográficos
Autores principales:	Riboldi, Ilaria, Cavaleri, Daniele, Capogrosso, Chiara A, Crocamo, Cristina, Bartoli, Francesco, Carrà, Giuseppe
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Dove 2022
Materias:	Review
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9809355/ https://www.ncbi.nlm.nih.gov/pubmed/36605176 http://dx.doi.org/10.2147/PRBM.S371991

Ejemplares similares

Long-acting injectable antipsychotics for the treatment of bipolar disorder: evidence from mirror-image studies
por: Bartoli, Francesco, et al.
Publicado: (2023)

Digital mental health interventions for anxiety and depressive symptoms in university students during the COVID-19 pandemic: A systematic review of randomized controlled trials
por: Riboldi, Ilaria, et al.
Publicado: (2023)

Efficacy of Cannabidiol for Δ-9-Tetrahydrocannabinol-Induced Psychotic Symptoms, Schizophrenia, and Cannabis Use Disorders: A Narrative Review
por: Bartoli, Francesco, et al.
Publicado: (2021)

Testing the Impact of Depressive and Anxiety Features on the Association between Attention-Deficit/Hyperactivity Disorder Symptoms and Academic Performance among University Students: A Mediation Analysis
por: Riboldi, Ilaria, et al.
Publicado: (2022)

Mental Health and COVID-19 in University Students: Findings from a Qualitative, Comparative Study in Italy and the UK
por: Riboldi, Ilaria, et al.
Publicado: (2023)

Pre-Discharge Predictors of 1-Year Rehospitalization in Adolescents and Young Adults with Severe Mental Disorders: A Retrospective Cohort Study
por: Bartoli, Francesco, et al.
Publicado: (2020)

Disentangling the Association between ADHD and Alcohol Use Disorder in Individuals Suffering from Bipolar Disorder: A Systematic Review and Meta-Analysis
por: Bartoli, Francesco, et al.
Publicado: (2021)

The Use of Long-Acting Injectable Antipsychotics in Schizophrenia
por: Miyamoto, Seiya, et al.
Publicado: (2017)

Guidance on the clinical understanding and use of long‐acting injectable antipsychotics in Schizophrenia: Hong Kong Consensus Statements
por: Wong, Michael Ming Cheuk, et al.
Publicado: (2021)

The association of kynurenine pathway metabolites with symptom severity and clinical features of bipolar disorder: An overview
por: Bartoli, Francesco, et al.
Publicado: (2022)

Long-Acting Injectable Antipsychotics in First-Episode Schizophrenia
por: Parellada, Eduard, et al.
Publicado: (2012)

Long-acting Injectable Antipsychotics in First-episode Schizophrenia
por: Jeong, Hyun-Ghang, et al.
Publicado: (2013)

The place of long-acting injectable antipsychotics in the treatment of schizophrenia
por: Kane, John M., et al.
Publicado: (2023)

Anterior pituitary hormones in first-episode psychosis: a systematic review and meta-analysis
por: Cavaleri, D., et al.
Publicado: (2023)

The modern perspective for long-acting injectables antipsychotics in the patient-centered care of schizophrenia
por: Pietrini, Francesco, et al.
Publicado: (2019)

Some of us are most at risk: Systematic review and meta-analysis of correlates of depressive symptoms among healthcare workers during the SARS-CoV-2 outbreak
por: Crocamo, Cristina, et al.
Publicado: (2021)

Reasons for initiating long-acting antipsychotics in psychiatric practice: findings from the STAR Network Depot Study
por: Barbui, Corrado, et al.
Publicado: (2020)

Long Acting Injectable Antipsychotics in the Treatment of Schizophrenia and Bipolar Disorder
por: DEVRİMCİ ÖZGÜVEN, Halise, et al.
Publicado: (2021)

Pharmacokinetic Characteristics of Long-Acting Injectable Antipsychotics for Schizophrenia: An Overview
por: Correll, Christoph U., et al.
Publicado: (2021)

Time to Rehospitalization in Patients With Schizophrenia Receiving Long-Acting Injectable Antipsychotics or Oral Antipsychotics
por: Lin, Ching-Hua, et al.
Publicado: (2019)

Comparison of Efficacy and Safety between Long-Acting Injectable Antipsychotic Monotherapy and Combination of Long-Acting Injectable and Oral Antipsychotics in Patients with Schizophrenia
por: Sathienluckana, Thanompong, et al.
Publicado: (2021)

Mental health and COVID-19 in university students: a qualitative study comparing Italy and the UK
por: Riboldi, I., et al.
Publicado: (2023)

Off–label long acting injectable antipsychotics in real–world clinical practice: a cross-sectional analysis of prescriptive patterns from the STAR Network DEPOT study
por: D’Agostino, Armando, et al.
Publicado: (2022)

Long-Acting Injectable Antipsychotics for First-Episode Schizophrenia: The Pros and Cons
por: Kim, Borah, et al.
Publicado: (2012)

Analysis of Oral versus Long-acting Injectable Antipsychotics in the Maintenance of Schizophrenia
por: Vasiliu, O.
Publicado: (2022)

Purinergic Signaling and Related Biomarkers in Depression
por: Bartoli, Francesco, et al.
Publicado: (2020)

Patient and Health Care Provider Perspectives on Long Acting Injectable Antipsychotics in Schizophrenia and the Introduction of Olanzapine Long-Acting Injection
por: Wehring, Heidi J., et al.
Publicado: (2011)

Clinical benefits and impact of early use of long‐acting injectable antipsychotics for schizophrenia
por: Stevens, Georgia L., et al.
Publicado: (2015)

Clinical Decision-Making in the Treatment of Schizophrenia: Focus on Long-Acting Injectable Antipsychotics
por: Samalin, Ludovic, et al.
Publicado: (2016)

Attitudes toward long-acting injectable antipsychotics among patients with schizophrenia in Japan
por: Sugawara, Norio, et al.
Publicado: (2019)

Aripiprazole Lauroxil: Pharmacokinetic Profile of This Long-Acting Injectable Antipsychotic in Persons With Schizophrenia
por: Hard, Marjie L., et al.
Publicado: (2017)

The Effect of Switching to Long-Acting Injection (LAI) Antipsychotic Therapy on Patients with Schizophrenia
por: STRUNOIU, LIVIA MIHAELA, et al.
Publicado: (2021)

The Effect of Longer Dosing Intervals for Long-Acting Injectable Antipsychotics on Outcomes in Schizophrenia
por: Milz, Ruth, et al.
Publicado: (2023)

The combination of long-acting injectable antipsychotics, a new key in resistant schizophrenia
por: Tascón Guerra, M.F., et al.
Publicado: (2022)

Patient perspectives in the development and use of long-acting antipsychotics in schizophrenia: focus on olanzapine long-acting injection
por: Citrome, Leslie
Publicado: (2009)

Long-Acting Injectable Antipsychotics in Schizophrenia: Literature Review and Practical Perspective, with a Focus on Aripiprazole Once-Monthly
por: Biagi, Enrico, et al.
Publicado: (2017)

Detecting Binge Drinking and Alcohol-Related Risky Behaviours from Twitter’s Users: An Exploratory Content- and Topology-Based Analysis
por: Crocamo, Cristina, et al.
Publicado: (2020)

Treatment Adherence with Early Prescription of Long-Acting Injectable Antipsychotics in Recent-Onset Schizophrenia
por: Viala, Annie, et al.
Publicado: (2012)

Second-generation long-acting injectable antipsychotics in schizophrenia: patient functioning and quality of life
por: Montemagni, Cristiana, et al.
Publicado: (2016)

T167. QUALITATIVE DIFFERENCES IN LONG ACTING INJECTABLE ANTIPSYCHOTIC MEDICATIONS AMONG SCHIZOPHRENIA PATIENTS
por: Karakasi, Valeria, et al.
Publicado: (2020)

Cannot write session to /tmp/vufind_sessions/sess_k7t5bhsv5euhaeo7mnu35mo6d6